Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 473

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

Open access
Herrero, Rolando, Quint, Wim, Hildesheim, Allan, Gonzalez, Paula, Struijk, Linda, Katki, Hormuzd A., Porras, Carolina, Schiffman, Mark, Rodriguez, Ana Cecilia, Solomon, Diane, Jimenez, Silvia, Schiller, John T., Lowy, Douglas R., van Doorn, Leen-Jan, Wacholder, Sholom, Kreimer, Aimée R., for the CVT Vaccine Group·2013·PLoS ONE
DOI 10.1371/journal.pone.0068329
Open this paper in CoChat — free account

Abstract

BACKGROUND: Human papillomavirus (HPV) infection, particularly with type 16, causes a growing fraction of oropharyngeal cancers, whose incidence is increasing, mainly in developed countries. In a double-blind controlled trial conducted to investigate vaccine efficacy (VE) of the bivalent HPV 16/18 vaccine against cervical infections and lesions, we estimated VE against prevalent oral HPV infections 4 years after vaccination. METHODS AND FINDINGS: A total of 7,466 women 18-25 years old were randomized (1∶1) to receive the HPV16/18 vaccine or hepatitis A vaccine as control. At the final blinded 4-year study visit, 5,840 participants provided oral specimens (91·9% of eligible women) to evaluate VE against oral infections. Our primary analysis evaluated prevalent oral HPV infection among all vaccinated women with oral and cervical HPV results. Corresponding VE against prevalent cervical HPV16/18 infection was calculated for comparison. Oral prevalence of identifiable mucosal HPV was relatively low (1·7%). Approximately four years after vaccination, there were 15 prevalent HPV16/18 infections in the control group and one in the vaccine group, for an estimated VE of 93·3% (95% CI = 63% to 100%). Corresponding efficacy against prevalent cervical HPV16/18 infection for the same cohort at the same visit was 72·0% (95% CI = 63% to 79%) (p versus oral VE = 0·04). There was no statistically significant protection against other oral HPV infections, though power was limited for these analyses. CONCLUSIONS: HPV prevalence four years after vaccination with the ASO4-adjuvanted HPV16/18 vaccine was much lower among women in the vaccine arm compared to the control arm, suggesting that the vaccine affords strong protection against oral HPV16/18 infection, with potentially important implications for prevention of increasingly common HPV-associated oropharyngeal cancer. ClinicalTrials.gov, Registry number NCT00128661.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0068329

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 473

Metadata

Authors
Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., Porras, C., Schiffman, M., Rodriguez, A. C., Solomon, D., Jimenez, S., Schiller, J. T., Lowy, D. R., van Doorn, L.-J., Wacholder, S., Kreimer, A. R., & for the CVT Vaccine Group
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-07-17
Volume
8
Issue
7
Pages
e68329
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0068329
OpenAlex
W2113000896
Cited by
473
References
27
FWCI
38.92
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. https://app.cochat.ai/papers/10.1371/journal.pone.0068329
The paper
Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., Porras, C., Schiffman, M., Rodriguez, A. C., Solomon, D., Jimenez, S., Schiller, J. T., Lowy, D. R., van Doorn, L.-J., Wacholder, S., Kreimer, A. R., & for the CVT Vaccine Group. (2013). Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS ONE. https://doi.org/10.1371/journal.pone.0068329

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.